Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

Aβ42 (blood)

Method of Measurement (Pre-analytical Tools)
Blood/Plasma
Biomarker Measured
Amyloid
Use
Diagnostic
Stage of Development
Clinical trials
Active vs Completed Trials
Completed
Aim/Results

Blood plasma Aβ42 shows similar amyloid-associated alterations as previously reported in cerebrospinal fluid, suggesting a blood-brain transportation mechanism of Aβ. The stability and sensitivity of plasma Aβ measurements suggest this may be a useful screening test for central nervous system amyloidosis.

What is Required from Patients

blood draw, mild discomfort, in clinic visits

What is Required from the Health System

phlebotomist, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g., mass spectrometer, protein assay kit, ELISA, or western blot)

Sponsor

Washington University School of Medicine

  1. “Closing in on a Blood Test for Alzheimer’s.” Alzforum. https://www.alzforum.org/news/research-news/closing-blood-test-alzheimers

  2. Ovod, V., Ramsey, K. N., Mawuenyega, K. G., Bollinger, J. G., Hicks, T., Schneider, T., ... & Benzinger, T. (2017). Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimer's & Dementia, 13(8), 841-849. https://www.ncbi.nlm.nih.gov/pubmed/28734653

  3. Sharma, N., & Singh, A. N. (2016). Exploring biomarkers for Alzheimer’s disease. Journal of clinical and diagnostic research: JCDR, 10(7), KE01. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5020308/